케타민의 항우울 효과와 임상적 적용
The Antidepressant Effects and Clinical Implication of Ketamine
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Major depressive disorder is a highly prevalent psychiatric condition that causes serious health concern and psychosocial consequences. Nevertheless, about one third of the patients with major depressive disorder have treatmentresistant depression (i.e., a failure to respond to two or more antidepressant drugs). In addition, it takes at least two weeks to several months before the antidepressants have an effect. In the field of emergency psychiatry, this time lag has always been a serious obstacle in the treatment of suicidal patients. Since 2000, the ketamine has emerged as a novel therapeutic agent for major depressive disorder and suicidality with rapid onset and robust response rates. In 2019, the U.S. Food and Drug Administration (U.S. FDA) approved the S-enantiomer of ketamine, esketamine as a drug for treatment-resistant depression. However, the U.S. FDA approved it with a Risk Evaluation and Mitigation Strategy (REMS) to mitigate the risk of serious adverse effects resulting from sedation, dissociation, cardiovascular instability, and potential abuse. Although we still do not have enough experience about the efficacy and safety of this new medication, the interests of clinicians and patients are rapidly growing. In this narrative review, the pharmacological characteristics, the mechanism of action, the psychiatric effects and side effects, and a consensus statement on the use of ketamine were provided.
Abstract
Major depressive disorder is a highly prevalent psychiatric condition that causes serious health concern and psychosocial consequences. Nevertheless, about one third of the patients with major depressive disorder have treatmentresistant depression (i.e., a failure to respond to two or more antidepressant drugs). In addition, it takes at least two weeks to several months before the antidepressants have an effect. In the field of emergency psychiatry, this time lag has always been a serious obstacle in the treatment of suicidal patients. Since 2000, the ketamine has emerged as a novel therapeutic agent for major depressive disorder and suicidality with rapid onset and robust response rates. In 2019, the U.S. Food and Drug Administration (U.S. FDA) approved the S-enantiomer of ketamine, esketamine as a drug for treatment-resistant depression. However, the U.S. FDA approved it with a Risk Evaluation and Mitigation Strategy (REMS) to mitigate the risk of serious adverse effects resulting from sedation, dissociation, cardiovascular instability, and potential abuse. Although we still do not have enough experience about the efficacy and safety of this new medication, the interests of clinicians and patients are rapidly growing. In this narrative review, the pharmacological characteristics, the mechanism of action, the psychiatric effects and side effects, and a consensus statement on the use of ketamine were provided.
참고문헌 (47)
- 2016 The Survey of Mental Disorders in Korea, "Hong JP", Ministry of health and welfare, ~ (2017)
- Greenberg PE, "The economic burden of adults with major depressive disorder in the United States(2005 and 2010)", J Clin Psychiatry, 76, pp.155~162 (2015)
- Walker ER, "Mortality in mental disorders and global disease burden implications : a systematic review and meta-analysis", JAMA Psychiatry, 72, pp.334~341 (2015)
- Rush AJ, "Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps : a STAR*D report", Am J Psychiatry, 163, pp.1905~1917 (2006)
- Hantouche E, "Explained factors of suicide attempts in major depression", J Affect Disord, 127, pp.305~308 (2010)
- Kim J, "Esketamine for treatment-resistant depression-first FDAapproved antidepressant in a new class", N Engl J Med, 381, pp.1~4 (2019)
- Domino EF, "Taming the ketamine tiger. 1965", Anesthesiology, 113, pp.678~684 (2010)
- Li L, "Ketamine : 50 years of modulating the mind", Front Hum Neurosci, 10, pp.612~ (2016)
- Niciu MJ, "Glutamate receptor antagonists as fastacting therapeutic alternatives for the treatment of depression : ketamine and other compounds", Annu Rev Pharmacol Toxicol, 54, pp.119~139 (2014)
- Andrade C, "Ketamine for depression, 5 : potential pharmacokinetic and pharmacodynamic drug interactions", J Clin Psychiatry, 78, pp.e858~61 (2017)
- Muller J, "Ketamine enantiomers in the rapid and sustained antidepressant effects", Ther Adv Psychopharmacol, 6, pp.185~192 (2016)
- Zeilhofer HU, "Differential-effects of ketamine enantiomers on NMDA receptor currents in cultured neurons", Eur J Pharmacol, 213, pp.155~158 (1992)
- Yang C, "R-ketamine : a rapid-onset and sustained antidepressant without psychotomimetic side effects", Transl Psychiatry, 5, pp.e632~ (2015)
- Zanos P, "NMDAR inhibition-independent antidepressant actions of ketamine metabolites", Nature, 533, pp.481~486 (2016)
- Daly EJ, "Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression : a randomized clinical trial", JAMA Psychiatry, 75, pp.139~148 (2018)
- Quintana DS, "The promise and pitfalls of intranasally administering psychopharmacological agents for the treatment of psychiatric disorders", Mol Psychiatry, 21, pp.29~38 (2016)
- Zanos P, "Mechanisms of ketamine action as an antidepressant", Mol Psychiatry, 23, pp.801~811 (2018)
- Moghaddam B, "Activation of glutamatergic neurotransmission by ketamine : a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex", J Neurosci, 17, pp.2921~2927 (1997)
- Chowdhury GMI, "Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects", Mol Psychiatry, 22, pp.120~126 (2017)
- Miller OH, "GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine", Elife, 3, pp.e03581~ (2014)
- Wang CC, "A critical role for GluN2B-containing NMDA receptors in cortical development and function", Neuron, 72, pp.789~805 (2011)
- Autry AE, "NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses", Nature, 475, pp.91~95 (2011)
- Berman RM, "Antidepressant effects of ketamine in depressed patients", Biol Psychiatry, 47, pp.351~354 (2000)
- Zarate CA Jr, "A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression", Arch Gen Psychiatry, 63, pp.856~864 (2006)
- Mathew SJ, "Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial", Int J Neuropsychopharmacol, 13, pp.71~82 (2010)
- Ibrahim L, "Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study", Neuropsychopharmacology, 37, pp.1526~1533 (2012)
- Murrough JW, "Antidepressant efficacy of ketamine in treatment-resistant major depression: a twosite randomized controlled trial", Am J Psychiatry, 170, pp.1134~1142 (2013)
- Murrough JW, "Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression", Biol Psychiatry, 74, pp.250~256 (2013)
- Shiroma PR, "Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression", J Affect Disord, 155, pp.123~129 (2014)
- Singh JB, "A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression", Am J Psychiatry, 173, pp.816~826 (2016)
- Wilkinson ST, "The effect of a single dose of intravenous ketamine on suicidal ideation : a systematic review and individual participant data meta-analysis", Am J Psychiatry, 175, pp.150~158 (2018)
- Short B, "Side-effects associated with ketamine use in depression : a systematic review", Lancet Psychiatry, 5, pp.65~78 (2018)
- Pomarol-Clotet E, "Psychological effects of ketamine in healthy volunteers. Phenomenological study", Br J Psychiatry, 189, pp.173~179 (2006)
- Singh I, "Ketamine treatment for depression : opportunities for clinical innovation and ethical foresight", Lancet Psychiatry, 4, pp.419~426 (2017)
- Lu Y, "Tolerance to the cataleptic effect of the N-methyl-D-aspartate(NMDA)receptor antagonists in pigeons : cross-tolerance between PCPlike compounds and competitive NMDA antagonists", J Pharmacol Exp Ther, 263, pp.499~504 (1992)
- Moreton JE, "Ketamine self-administration by the rhesus monkey", J Pharmacol Exp Ther, 203, pp.303~309 (1977)
- World Health Organization, "WHO model prescribing information: Drugs used in anaesthesia" (1989), World Health Organization
- Morgan CJA, "Ketamine use: a review", Addiction, 107, pp.27~38 (2012)
- Winstock AR, "The prevalence and natural history of urinary symptoms among recreational ketamine users", BJU Int, 110, pp.1762~1766 (2012)
- Cheung RY, "Urinary symptoms and impaired quality of life in female ketamine users : persistence after cessation of use", Hong Kong Med J, 17, pp.267~273 (2011)
- Noppers IM, "Drug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients : a report of 3 cases", Pain, 152, pp.2173~2178 (2011)
- "Approved risk evaluation and mitigation strategies (REMS)" (2019)[URL]
- Sanacora G, "A consensus statement on the use of ketamine in the treatment of mood disorders", JAMA Psychiatry, 74, pp.399~405 (2017)
- Xu Y, "Effects of low-dose and very low-dose ketamine among patients with major depression : a systematic review and meta-analysis", Int J Neuropsychopharmacol, 19 (2016)
- Molero P, "Antidepressant efficacy and tolerability of ketamine and esketamine : a critical review", CNS Drugs, 32, pp.411~420 (2018)
- Wan LB, "Ketamine safety and tolerability in clinical trials for treatment-resistant depression", J Clin Psychiatry, 76, pp.247~252 (2015)
- Singh JB, "Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study", Biol Psychiatry, 80, pp.424~431 (2016)